Arvinas has been granted a patent for bifunctional compounds capable of degrading and inhibiting Androgen Receptor. The compounds contain a cereblon ligand and a moiety binding Androgen Receptor, facilitating degradation. The patent covers a broad range of pharmacological activities associated with Androgen Receptor degradation. GlobalData’s report on Arvinas gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Arvinas Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Arvinas, Cancer treatment biomarkers was a key innovation area identified from patents. Arvinas's grant share as of April 2024 was 21%. Grant share is based on the ratio of number of grants to total number of patents.

Bifunctional compounds degrading and inhibiting androgen receptor

Source: United States Patent and Trademark Office (USPTO). Credit: Arvinas Inc

The granted patent (Publication Number: US11964945B2) discloses a compound represented by the structure ABM-L-CLM, or a pharmaceutically acceptable salt thereof. The compound includes various components such as ABM, W1, W2, and a chemical linker group (L). Additionally, the patent claims a pharmaceutical composition comprising an effective amount of the compound along with a pharmaceutically acceptable carrier, which may further include an anti-cancer agent. The patent also specifies different configurations and variations of the compound based on the values of n and R, providing a detailed description of the possible combinations and structures.

Furthermore, the patent outlines specific characteristics and options for the compound, such as the selection of AL from CRL1RL2 and C3-11 heterocyclyl, with examples including CH2, piperazinyl, and piperidinyl. The variations in n and R further define the composition of the compound, offering a range of possibilities for customization based on the desired properties and applications. Overall, the patent provides a comprehensive overview of the compound's structure, composition, and potential pharmaceutical uses, highlighting the versatility and flexibility in designing molecules with specific functionalities and therapeutic benefits.

To know more about GlobalData’s detailed insights on Arvinas, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies